This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in this journal  Topic Collections  • Patient Safety/ Medical Error  • Renal Diseases, Other  • Alert me on articles by topic  Social Bookmarking   What's this?

Lisa M. Einhorn, BS; Min Zhan, PhD; Van Doren Hsu, PharmD; Lori D. Walker, BS; Maureen F. Moen, BS; Stephen L. Seliger, MD, MS; Matthew R. Weir, MD; Jeffrey C. Fink, MD, MS

Arch Intern Med. 2009;169(12):1156-1162.

Background  Hyperkalemia is a potential threat to patient safety in chronic kidney disease (CKD). This study determined the incidence of hyperkalemia in CKD and whether it is associated with excess mortality.

Methods  This retrospective analysis of a national cohort comprised 2 103 422 records from 245 808 veterans with at least 1 hospitalization and at least 1 inpatient or outpatient serum potassium record during the fiscal year 2005. Chronic kidney disease and treatment with angiotensin-converting enzyme inhibitors and/or angiotensin II receptor blockers (blockers of the renin-angiotensin-aldosterone system [RAAS]) were the key predictors of hyperkalemia. Death within 1 day of a hyperkalemic event was the principal outcome.

Results  Of the 66 259 hyperkalemic events (3.2% of records), more occurred as inpatient events (n = 34 937 [52.7%]) than as outpatient events (n = 31 322 [47.3%]). The adjusted rate of hyperkalemia was higher in patients with CKD than in those without CKD among individuals treated with RAAS blockers (7.67 vs 2.30 per 100 patient-months; P < .001) and those without RAAS blocker treatment (8.22 vs 1.77 per 100 patient-months; P < .001). The adjusted odds ratio (OR) of death with a moderate (potassium, 5.5 and <6.0 mEq/L [to convert to mmol/L, multiply by 1.0]) and severe (potassium, 6.0 mEq/L) hyperkalemic event was highest with no CKD (OR, 10.32 and 31.64, respectively) vs stage 3 (OR, 5.35 and 19.52, respectively), stage 4 (OR, 5.73 and 11.56, respectively), or stage 5 (OR, 2.31 and 8.02, respectively) CKD, with all P < .001 vs normokalemia and no CKD.

Conclusions  The risk of hyperkalemia is increased with CKD, and its occurrence increases the odds of mortality within 1 day of the event. These findings underscore the importance of this metabolic disturbance as a threat to patient safety in CKD.

Author Affiliations: Departments of Medicine (Mss Einhorn and Moen and Drs Seliger, Weir, and Fink) and Epidemiology and Preventive Medicine (Drs Zhan, Seliger, and Fink), University of Maryland School of Medicine, and Pharmaceutical Research Computing, University of Maryland School of Pharmacy (Dr Hsu and Ms Walker), Baltimore.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED ARTICLE

In This Issue of Archives of Internal Medicine
Arch Intern Med. 2009;169(12):1094.
FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Mineralocorticoid Receptor Blockers and Chronic Kidney Disease
Jain et al.
CJASN 2009;4:1685-1691.
ABSTRACT | FULL TEXT